Drug intelligence / Profile preview

TV-400

Development stage: Preclinical
Lead developer: TheraVac Biologics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TV-400 is a virus-like particle (VLP)-based active immunotherapy (vaccine) currently in preclinical development by TheraVac Biologics for the treatment of Spinal Muscular Atrophy (SMA). The candidate utilizes a multivalent display of immunogenic peptides on a VLP platform to stimulate a targeted immune response. TV-400 has been granted Orphan Disease designation and is approximately 50% through the preclinical phase of development.

Beyond the preview

Go deeper on TV-400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TV-400.

Explore the full profile